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ABSTRACT
Background and aims Smoking during pregnancy is strongly associated with negative pregnancy and perinatal out-
comes. Some guidelines recommend nicotine replacement therapy (NRT) for smoking cessation during pregnancy, but ad-
herence with NRT is generally poor and could be partially explained by nicotine-related safety concerns. We compared
pregnant women’s cotinine and nicotine exposures from smoking with those when they were abstinent from smoking
and using NRT. Design Systematic review with meta-analysis and narrative reporting. Twelve studies were included:
in most, only one type of NRT was used. Seven were quality-assessed and judge of variable quality. Setting Studies from
any setting that reported nicotine or cotinine levels when smoking and later when abstinent and using NRT.
Participants Pregnant womenwho smoked and became abstinent but used NRTeither in a cessation study or in a study
investigatingother impacts of NRT.Measurements We quality-assessed longitudinal cohort studies using amodiﬁed ver-
sion of the Newcastle–Ottawa scale. For meta-analysis, we used mean within-person differences in cotinine or nicotine
levels when smoking and at later follow-up when abstinent and using NRT. Where such data were not available, we cal-
culated differences in group mean levels and reported these narratively, indicating where data were not completely longi-
tudinal. Findings Of the 12 included studies, four cotinine-measuring studies (n = 83) were combined in a random
effects meta-analysis; the pooled estimate for the mean difference (95% conﬁdence intervals) in cotinine levels between
when women were smoking and abstinent but using NRT was 75.3 (57.1 to 93.4) ng/ml (I2 = 42.1%, P = 0.11). Of eight
narratively-described studies, six reported lower cotinine and/or nicotine levels when abstinent and using NRT; two had
mixed ﬁndings, with higher levels when abstinent but using NRT reported from at least one assay time-point.
Conclusions Pregnant women who use nicotine replacement therapy instead of smoking reduce their nicotine
exposure.
Keywords Cotinine, nicotine, nicotine replacement therapy, pregnancy, smoking, smoking cessation.
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INTRODUCTION
Smoking in pregnancy causes muchmorbidity andmortal-
ity [1] and rates are highest among younger, socially disad-
vantaged women [2]. Forty per cent of socio-economic
inequalities in stillbirths and infant deaths are smoking-
related [3], and smokers’ children are twice as likely to be-
come smokers themselves [4]; however, this is all avoidable.
Stopping smoking in pregnancy improves birth outcomes
[5]; permanent cessation after pregnancy improves
women’s health and may also improve their children’s
health by diminishing second-hand smoke exposure and
possibly by reducing penetration of smoking across the
generations [6].
In the United Kingdom, when other cessation methods
have been ineffective, pregnant women who want to stop
can be recommended to use nicotine replacement therapy
(NRT) [7] and guidance developed for use across the Euro-
pean Union (EU) takes the same approach [8]. All UK stop
smoking services (SSS) offer NRT to pregnant smokers [9],
and 11% of UK pregnant smokers receive NRT prescrip-
tions [10]. Although NRT is effective outside pregnancy
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and the risk ratio (RR) [95% conﬁdence interval (CI)] for
cessation using NRT in non-pregnant smokers is 1.60
(1.53–1.68) [11], in pregnancy NRT has, at best, only bor-
derline effectiveness for promoting smoking cessation.
From all trials of NRT in pregnancy, the risk ratio (95%
CI) for cessation with NRT in pregnancy is 1.43 (1.03–
1.93), but when meta-analysis is restricted to include only
least-biased, placebo randomized controlled trials (RCTs),
there is less evidence that NRT works and the risk ratio
(RR) is reduced further (RR 1.28, 95% CI = 0.99–1.66)
[12]. One of the most plausible explanations for NRT
appearing less effective in pregnancy is that pregnant
women may not use NRT for long enough or in sufﬁcient
doses for it to be effective. For example, of UK pregnant
smokers who are offered or prescribed NRT, 70% receive
only a 2-week supply [10]. Similarly, in some trials which
have enrolled pregnant smokers, only 7–30% of partici-
pants completed recommended courses of NRT [12]. In
contrast, non-pregnant smokers enrolled into cessation tri-
als adheremore strongly, using up to 94% of their intended
NRT treatment courses [13].
Improving pregnant smokers’ adherence to NRT could
result in this being more effective at helping them to stop
smoking. In non-pregnant smokers, prescribing higher
doses of NRT results in greater use of NRT [13], and this
greater use of NRT is causally associated with successfully
stopping smoking [13,14]. There is very little similar re-
search in pregnancy; however, we know that the rate of
nicotine metabolism is substantially accelerated in preg-
nancy [15,16]. This means that any given dose of NRT
generates lower blood nicotine concentrations than the
same dose used either before pregnancy or in the postpar-
tum period. It is also known that, in pregnancy, faster nic-
otine metabolism is associated with lower cessation rates
[17], possibly because pregnant NRTusers havemore rapid
nicotine turnover and so will experience stronger nicotine
withdrawal symptoms, be more likely to perceive NRT as
unhelpful and stop using it. One would therefore only ex-
pect NRT to be as effective during pregnancy as it is either
before or afterwards if pregnant women’s adherence levels
were improved such that they obtained sufﬁcient nicotine
to ameliorate the impact of increased metabolism.
Pregnant women’s reluctance to use NRT seems to be
partially explained by their worries about the safety of nic-
otine [18]. However, as NRT contains none of the harmful
products of tobacco combustion there has long been con-
sensus that, for pregnant women, NRT is probably safer
than smoking [19]. Nevertheless, as we cannot be
completely sure that nicotine is entirely safe in pregnancy,
women probably need reassurance. Hence, to help preg-
nant women to decide about using NRT, clear information
about nicotine exposures generated when smoking or
using NRTcould be useful. Such information could also as-
sist health professionals who counsel pregnant women
about using NRT. In this review, therefore, we aimed to
identify and describe studies which report nicotine or cotin-
ine levels in pregnant women when smoking and subse-
quently when abstinent from smoking and using NRT,
comparing these to estimate any differences between body
ﬂuid concentrations. A secondary aim was to investigate
how any differences might be inﬂuenced by type(s) of
NRT used or health professionals’ instructions on how
NRT should be used.
METHOD
This review followed the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) methods
[20]. A review protocol has been published [21]. To be in-
cluded, papers needed to study pregnant women who
smoke and who subsequently became abstinent while
using NRT. Studies had to report the same women’s nico-
tine or cotinine body ﬂuid levels both when smoking and
when using NRT. The design had to either be longitudinal
or have a design which implied that longitudinal data
might be available, even if such data were not reported in
study publications (e.g. from NRT-allocated arms in RCTs
of NRT).
Searches
We developed a search strategy in MEDLINE using a com-
bination ofMESH and plain text terms and adapted it to use
inWeb of Science and EBSCO (see Supporting information,
Appendix S1); the strategy was optimized against its ability
to ﬁnd three studies which we knew should be included in
the ﬁnal review. Searches of these three platforms allowed
access to six databases: MEDLINE, EMBASE (Excerpta
Medica Database), PsycINFO, MIDRIS (Maternity and In-
fant Care Database), SSCI (Social Sciences Citation Index)
and CINHAL (Cumulative Index to Nursing and Allied
Health Literature), and were completed by 29 August
2017. We also searched GSK clinical trials (https://www.
gsk-clinicalstudyregister.com/);World Health Organization
International Clinical Trials Registry Platform (www.who.
int/trialsearch); US National Library of Medicine Clinical
Trials database (clinicaltrials.gov/); and the ISRCTN regis-
try (http://www.isrctn.com/). Finally, we searched the
Cochrane Library using the terms ‘smoking’, ‘pregnancy’
and ‘nicotine replacement’. Non-bibliographic database
searches were completed by 7 September 2017. There
were no language restrictions and literature was searched
from 1980, as the ﬁrst trials of NRT were reported after
that. In tandem with electronic searches, we scanned the
references of papers included in reviews identiﬁed by the
searches, and which covered the topic of interest, but were
not eligible for inclusion.
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Study selection
Identiﬁed citations (titles and abstracts) were manipulated
in an EndNote library. One reviewer (C.H.) screened these
to assess whether or not articles should be included, and
where there was uncertainty or papers were thought likely
to be eligible, full texts were assessed by two reviewers with
agreement on inclusion or exclusion being reached by
consensus.
Data extraction
Data were extracted by one researcher (C.H.) and checked
by a second (T.C.). The following study details were ex-
tracted: objectives, setting, inclusion and exclusion criteria,
study design and analysis; and number and characteristics
of participants providing data for this review, baseline infor-
mation on nicotine addiction or heaviness of smoking. The
following intervention details were extracted: completeness
of follow-up for women in longitudinal analyses; reasons
for dropout; biochemical conﬁrmation of participant’s
smoking abstinence or not; dose(s) and type(s) of NRTused;
instructions given on how regularly and for how long NRT
should be used. The following details on measurements
were extracted: body ﬂuids sampled; whether nicotine or
cotinine was assayed; time-points at which samples were
taken and timings of samples relative to smoking or NRT
use; and relevant numerical ﬁndings (e.g. mean differences
between concentrations of cotinine or nicotine concentra-
tions at baseline and later time-points). For ongoing stud-
ies, we e-mailed the Principal Investigator enquiring
whether data were available and we asked the same of cor-
responding authors for those papers which reported insuf-
ﬁcient data for meta-analysis (see ‘Analysis’ below). For two
studies [22,23] we converted graphical data to numerical
using WebPlotDigitizer software [24].
Risk of bias assessment
We quality-assessed those studies which had been designed
as longitudinal cohort studies and which stated, a priori,
that a reason for the study was to take measurements
when smoking and later abstinent and using NRT. These
studies designs were, therefore, directly relevant to this re-
view—any biases in methods used could be adjudged di-
rectly from published reports; this was performed using
Wells’ modiﬁed version of the Newcastle–Ottawa Scale
(NCOS) [25] (see Supporting information, Appendix S2).
Papers were independently rated by two researchers, rat-
ings were compared and disagreements resolved by discus-
sion. We did not quality-assess studies which had not been
designed as before–after longitudinal studies (e.g. RCTs or
secondary analysis of RCTs). For these studies, as studies’
datawere not being used in a manner consistent with their
designs (e.g. data from RCT arms treated as cohorts), the
quality of the original study would not necessarily be rele-
vant to review analyses. Similarly, where authors provided
additional, unpublished data, we did not attempt quality
assessment.
Modiﬁcations to the Newcastle–Ottawa scale
Wells’modiﬁed version of theNCOS allocates stars to reﬂect
study quality on eight items grouped under three domains:
selection or comparability of study group and ascertain-
ment of exposure/outcome [25]. We did not use three
NCOS items and amended others, such that the maximum
score was seven stars. Two items attracted up to two stars
(‘representativeness of cohort’ and ‘adequacy of cohort
follow-up’) and one star for the remaining three (ascertain-
ment of exposures, method for conﬁrming abstinence and
appropriateness of sample timing). We did not use the item
‘Selection of the non-exposed cohort’, as included studies
compared measurements from the same women at differ-
ent times and did not have non-exposed controls. ‘Demon-
stration that outcome of interest was not present at start of
study’ was irrelevant, as all studies measured outcomes
(e.g. cotinine) and ‘Comparability of cohorts on the basis
of the design or analysis’ was not discriminatory, as all
studies were longitudinal cohorts. All ﬁve items and
scoring are fully described in Supporting information,
Appendix S2.
Analysis
Longitudinal, within-person data, from the same women
at baseline and at later time-points, were used to estimate
the mean differences between body ﬂuid levels of nicotine
or cotinine when smoking and later when abstinent and
using NRT. We aimed to provide a pooled estimate of this
difference in body ﬂuid levels and to investigate the impacts
of the type and dose of NRT and gestational age, but antic-
ipated that the meta-analysis undertaken would depend
upon the available data and that a ﬁnal decision on which
studies (if any) to include in analyses would be taken once
available literature were identiﬁed. For inclusion in meta-
analyses, study manuscripts had to report such amean dif-
ference and its standard error or to report sufﬁcient other
data from which these could be calculated. Where such
data were not included in papers, we contacted authors
requesting either aggregated data as mean differences
and standard errors or as individual participants’ data. A
saliva : blood cotinine ratio has been reported as 1.01
(95% CI = 0.99–1.04) [26], so blood and saliva cotinine
levels were considered interchangeable; nicotine and cotin-
ine values and also urinary and saliva cotinine readings are
not interchangeable, so these data were not aggregated.
Meta-analysis was conducted in Stata version 15 using
the Metan command employing random-effects models
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[27] to provide a pooled, weighted estimate for the mean
difference in cotinine levels when smoking and later when
abstinent and using NRT [28]. Two studies reported inde-
pendent cohorts of women who had received different
types or combinations or NRT [29,30]. As we anticipated
that there would potentially be more variation between co-
horts reported within one study, exposed to different types,
doses or combinations of NRT than between cohorts re-
ported in different studies, we treated such cohorts as inde-
pendent studies in the random-effects meta-analysis.
Heterogeneity was assessed using the I2 statistic [31].
For studies which could not be included in meta-
analysis, we calculated differences in group mean levels
(of cotinine or nicotine) and report these narratively, indi-
cating where data were not completely longitudinal. For
studies which provided ‘within-participant’, longitudinal
data with no loss to follow-up, percentage nicotine substi-
tution was calculated by dividing follow-up mean cotinine
(nicotine) levels by baseline ones and multiplying by 100.
The percentage nicotine substitution measure indicates
how completely NRT substitutes for nicotine from smoked
tobacco.
RESULTS
After removing duplicates, 3576 potentially relevant cita-
tions were found from library databases (131 from other
sources, Fig. 1), 30 full texts were reviewed, one study
was ongoing [32], 12 studies were included in the review
and four were meta-analysed. Table 1 gives the studies’
characteristics, including the numbers of participants pro-
viding longitudinal data and hence which could potentially
be aggregated in a meta-analysis. This was not always the
total number of study participants; for example, from RCTs,
only women randomized receiving NRTcould provide such
data. Two study reports contained sufﬁcient data for inclu-
sion inmeta-analysis [29,30]. For another two, authors re-
analysed their data to provide sufﬁcient information
[27,39,40]. Eight studies were reported narratively; for
one of these, the authors provided sufﬁcient extra data for
a ‘within-person’ mean difference in urinary cotinine
values to be calculated; this could not be combined with
values obtained from saliva assays, however [38]. For the
seven remaining narratively reported studies, mean differ-
ences were calculated by subtracting published group
mean cotinine or nicotine levels when abstinent and using
NRT from those measured when smoking, ignoring
between-participant variability. In two of these seven stud-
ies, only some followed-up women were abstinent and
using NRT and these women could not be identiﬁed from
other study participants [22,37].
Characteristics of included studies
Seven studies were set in the United States [22,23,30,34–
36,38], two recruited fromDenmark [29,37] and one each
from France [39], United Kingdom [40] and Sweden [33].
Sevenwere longitudinal cohorts designed to investigate the
impacts of smoking and then NRT use in the same women
[23,29,30,33–36], and ﬁve were either RCTs [22,37–40]
or presented secondary analyses of RCT data [40]. Studies
tested 2 mg nicotine gum [29,33,38]; 4 mg gum [33]; 7
mg/24-hour1 nicotine patch [22]; 14 mg/24-hour nico-
tine patch [22]; 15 mg/16-hour nicotine patch
[29,30,37,40]; 15 mg/24-hour nicotine patch plus 2 mg
gum (often called ‘dual NRT’) [29]; 21 mg/24-hour nico-
tine patch [23,35]; 22 mg/24-hour patch [36]; nicotine
nasal spray [30]; and also individualized nicotine dosing
based on saliva cotinine levels [39]. Three papers reported
studies recruiting relatively early in pregnancy; two RCTs
reported women’s mean gestational age at enrolment as
17weeks [38,39] and another as 14weeks [40]. All except
one of the remaining studies (22 weeks) [29] reported
mean gestations at recruitment of 27 weeks or later. Tim-
ings for body ﬂuids sampling while using NRT varied
greatly; in laboratory (or in-patient) studies sampling oc-
curred within 1 hour [33]; at 30 minutes and 5 days
[34]; at up to 8 hours [23,35]; during a 4-day period
[36]; and at both 8 hours and 4 days [30]. In non-
laboratory studies (mainly RCTs), sampling occurred at
1–2 weeks [29], 8–11weeks and also 4 weeks before deliv-
ery [37]; 6 weeks [38]; 2–4 weeks [22], 4 weeks [40]; and
at both 2 and 8 weeks after starting NRT [39].
Quality assessment
Quality assessments are reported in Table 2. The seven lon-
gitudinal cohort studies were of variable quality; six were
awarded three or more stars out of seven. Studies used ap-
propriate biochemical validation methods and generally
scored well on follow-up completeness, but they scored less
strongly with regard to the timing of samples when
smoking or using NRTor in how abstinence was conﬁrmed
before or while using NRT, usually due to lack of detail in
study descriptions.
Studies’ ﬁndings
Meta-analysis
Data obtained from 83 participants in four saliva cotinine-
measuring studies were included in ameta-analysis (Fig. 2;
Table 3, rows 1–4) [29,30,39,40]. The pooled estimate for
the mean difference (95% CIs) between saliva cotinine
levels when smoking and when using NRT and abstinent
from smoking was 75.3 (57.1–93.4) ng/ml (I2 = 42.1%,
1Not all papers explicitly reported patch duration; where necessary this has been derived from knowledge of available nicotine patches.
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P = 0.1). Within these studies, percentage nicotine substi-
tution varied between 26.5% (2 mg gum) [29] and 60.0%
(15 mg/16-hour patch).
Narratively reported studies
In six of the eight narratively reported studies, irrespective
of body ﬂuid (or substance assayed), exposure levels were
higher when smoking than when abstinent and using
NRT. In the remaining two studies, ﬁndings were mixed
and details follow; Table 3 shows mean differences and ex-
plains which datawere used to derive these and reasons for
exclusion from meta-analysis. Also, numbers of partici-
pants for whom longitudinal data were available are given
and, as relevant, how these related to total study samples.
The study summarized in row 5 reported higher uri-
nary cotinine levels when smoking [35]. Although longitu-
dinal datawere available, ﬁndings from this study could not
be used for the meta-analysis as other studies in this anal-
ysis reported saliva cotinine.
In rows 6–9, four longitudinal cohort studies are de-
scribed [23,33–35]; in three, exposure measured as nico-
tine or cotinine was higher when smoking [23,33,34].
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram: study selection. From: Moher D, Liberati A,
Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.
PLoS Med 6(7): e1000097. https://doi.org/10.1371/journal.pmed1000097
5
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Ta
bl
e
1
Ch
ar
ac
te
ri
st
ic
s
of
in
cl
ud
ed
st
ud
ie
s.
St
ud
y
Pa
rt
ic
ip
an
ts
po
te
nt
ia
lly
pr
ov
id
in
g
lo
ng
itu
di
na
l
da
ta
(n
)
Ch
ar
ac
te
ri
st
ic
s
of
pa
rt
ic
ip
an
ts
Se
tt
in
g,
de
si
gn
&
ex
po
su
re
s
B
od
y
ﬂ
ui
d
us
ed
an
d
as
sa
y
tim
in
gs
A
ss
ay
re
su
lts
Co
h
or
t
st
u
di
es
G
en
ns
er
,M
ar
šá
l&
Br
an
tm
ar
k
19
75
[3
3]
12
Va
lu
es
ar
e
ra
ng
es
M
at
er
na
la
ge
20
–
31
ye
ar
sa
G
es
ta
tio
na
la
ge
33
–3
9
w
ee
ks
a
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
7–
20
a
Sw
ed
en
La
bo
ra
to
ry
-b
as
ed
lo
ng
itu
di
na
lc
oh
or
t
st
ud
y;
no
ta
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y
O
ne
of
ea
ch
be
lo
w
ex
po
su
re
w
as
us
ed
on
co
ns
ec
ut
iv
e
da
ys
:
•
1
‘s
ta
nd
ar
d’
ci
ga
re
tt
e:
ta
lk
in
g
no
t
pe
rm
itt
ed
an
d
de
ep
in
ha
la
tio
n
en
co
ur
ag
ed
;
av
er
ag
e
sm
ok
in
g
tim
e
w
as
5
m
in
ut
es
•
2
m
g
gu
m
ch
ew
ed
fo
r
30
m
in
ut
es
•
4
m
g
gu
m
ch
ew
ed
fo
r
30
m
in
ut
es
Bl
oo
d
ni
co
tin
e
5
an
d
30
m
in
ut
es
af
te
r
st
ar
tin
g
to
sm
ok
e
a
ci
ga
re
tt
e
30
an
d
60
m
in
ut
es
af
te
r
st
ar
tin
g
to
ch
ew
1
pi
ec
e
of
gu
m
M
ea
n
±
SE
M
(n
g/
m
l)
Sm
ok
in
g
(n
=
12
)
5
m
in
ut
es
41
.3
±
3.
5
30
m
in
ut
es
19
.6
±
1.
4
2
m
g
gu
m
(n
=
6)
30
m
in
ut
es
10
.4
±
0.
6
60
m
in
ut
es
10
.0
±
0.
7
4
m
g
gu
m
(n
=
6)
30
m
in
ut
es
17
.5
±
1.
3
60
m
in
ut
es
14
.7
±
1.
3
O
nc
ke
n
et
al
.1
99
6
[3
4]
15
Va
lu
es
ar
e
m
ea
ns
±
SD
M
at
er
na
la
ge
28
±
6b
W
ei
gh
t
(lb
)
16
9
±
29
b
G
es
ta
tio
na
la
ge
28
.1
±
3.
2b
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
19
±
6b
Fa
ge
rs
tr
öm
va
lu
e
5.
7
±
2b
U
ni
te
d
St
at
es
Lo
ng
itu
di
na
lc
oh
or
t
st
ud
y;
no
t
a
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y
W
om
en
al
lo
ca
te
d
to
re
ce
iv
e
a
5-
da
y
co
ur
se
of
2
m
g
N
R
T
gu
m
an
d
ad
vi
se
d
to
us
e
≥
6
pi
ec
es
/d
ay
bu
t
<
30
pi
ec
es
/d
ay
an
d
≤
2
pi
ec
es
/h
ou
r
O
bs
er
ve
d
ch
ew
in
g
to
en
su
re
pr
op
er
te
ch
ni
qu
e
on
ﬁ
rs
t
us
e
R
ep
or
te
d
da
ily
ad
he
re
nc
e
(m
ea
n
±
SD
)
D
ay
1,
6
±
3
pi
ec
es
,d
ay
2,
9
±
5,
da
y
3,
8
±
3,
da
y
4,
8
±
3,
da
y
5,
5
±
2
(la
st
da
y
w
as
on
ly
a
ha
lf-
da
y)
Bl
oo
d
co
tin
in
e
30
m
in
ut
es
af
te
r
la
st
ci
ga
re
tt
e
A
fte
r
5
da
ys
us
in
g
ni
co
tin
e
gu
m
w
hi
le
re
m
ai
ni
ng
ab
st
in
en
t
A
ls
o
pr
es
en
te
d
tr
ou
gh
an
d
pe
ak
ni
co
tin
e
le
ve
ls
af
te
r
sm
ok
in
g
on
e
ci
ga
re
tt
e
an
d
ch
ew
in
g
1
pi
ec
e
2
m
g
gu
m
M
ea
n
±
SD
(n
g/
m
l)
Sm
ok
in
g
(n
=
15
)
15
3
±
18
5
da
ys
gu
m
(n
=
15
)
33
±
8
1
ci
ga
re
tt
e
Tr
ou
gh
6.
7
±
0.
8
Pe
ak
19
.7
±
1.
5
1
pi
ec
e
2-
m
g
gu
m
Tr
ou
gh
3.
3
±
0.
5
Pe
ak
5.
7
±
0.
7
(C
on
ti
nu
es
)
6 C. Hickson et al.
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Ta
bl
e
1.
(C
on
tin
ue
d)
St
ud
y
Pa
rt
ic
ip
an
ts
po
te
nt
ia
lly
pr
ov
id
in
g
lo
ng
itu
di
na
l
da
ta
(n
)
Ch
ar
ac
te
ri
st
ic
s
of
pa
rt
ic
ip
an
ts
Se
tt
in
g,
de
si
gn
&
ex
po
su
re
s
B
od
y
ﬂ
ui
d
us
ed
an
d
as
sa
y
tim
in
gs
A
ss
ay
re
su
lts
O
nc
ke
n
et
al
.1
99
7
[3
5]
15
Va
lu
es
ar
e
m
ea
ns
±
SD
M
at
er
na
la
ge
28
±
5.
4
G
es
ta
tio
na
la
ge
28
w
ee
ks
,3
da
ys
±
20
da
ys
H
ei
gh
t
16
1
±
5.
9
cm
W
ei
gh
t
63
.3
±
9.
2
kg
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
20
.2
±
5.
2
Va
lu
es
ar
e
ns
Et
hn
ic
ity
da
ta
W
hi
te
10
Bl
ac
k
2
H
is
pa
ni
c
3
U
ni
te
d
st
at
ed
La
bo
ra
to
ry
-b
as
ed
lo
ng
itu
di
na
lc
ro
ss
-o
ve
r
st
ud
y;
no
ta
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y
Tw
o
gr
ou
ps
of
w
om
en
us
ed
Bo
th
gr
ou
ps
:
Sm
ok
ed
ad
lib
itu
m
fo
r
8
ho
ur
s
A
bs
tin
en
tf
or
13
ho
ur
s
be
fo
re
pl
ac
em
en
to
f
a
21
-m
g
tr
an
sd
er
m
al
ni
co
tin
e
pa
tc
h
fo
r
8
ho
ur
s
Th
ey
w
er
e
ra
nd
om
iz
ed
to
ei
th
er
sm
ok
in
g
or
pa
tc
h
us
e
in
se
ss
io
n
1
an
d
th
en
a
w
ee
k
la
te
r
cr
os
se
d
ov
er
to
th
e
ot
he
r
ex
pe
ri
m
en
ta
l
co
nd
iti
on
Bl
oo
d
ni
co
tin
e
H
ou
rl
y
as
sa
ys
w
he
n
sm
ok
in
g
A
ss
ay
s
at
2
3,
4,
6
&
8
ho
ur
s
af
te
r
pl
ac
em
en
t
of
ni
co
tin
e
pa
tc
h
M
ax
im
um
m
ea
n
ni
co
tin
e
co
nc
en
tr
at
io
n,
tim
e
to
re
ac
h
m
ax
.a
nd
th
e
m
ea
n
ar
ea
pl
as
m
a
ni
co
tin
e
co
nc
en
tr
at
io
n-
tim
e
cu
rv
e
w
er
e
re
po
rt
ed
in
th
e
te
xt
of
th
is
pa
pe
r
M
ea
n
±
SD
(n
g/
m
l)
M
ax
im
al
pl
as
m
a
le
ve
ls
m
ok
in
g
19
.7
±
8.
09
Pa
tc
h
16
.0
±
3.
5
Ti
m
e
to
re
ac
h
m
ax
Sm
ok
in
g
5
ho
ur
s
±
2.
4
Pa
tc
h
3.
2
ho
ur
s
±
1.
7
A
re
a
un
de
r
th
e
pl
as
m
a
N
ic
ot
in
e
co
nc
en
tr
at
io
n
tim
e
cu
rv
e
Sm
ok
in
g
89
ng
ho
ur
/m
l
Pa
tc
h
93
ng
ho
ur
/m
l
M
ea
n
di
ffe
re
nc
e
±
SE
M
4.
8
±
10
.3
ng
ho
ur
/m
l
W
ri
gh
te
ta
l.
19
97
[2
3]
6
Va
lu
es
ar
e
m
ea
ns
&
ra
ng
es
M
at
er
na
la
ge
25
.7
(2
1–
31
)
W
ei
gh
t
82
.0
5
kg
(6
6.
1–
87
.5
kg
)
G
es
ta
tio
na
la
ge
34
.2
(2
8.
1–
37
)
A
ll
w
hi
te
pa
rt
ic
ip
an
ts
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
½
–
2
pa
ck
s
U
ni
te
d
St
at
es
La
bo
ra
to
ry
-b
as
ed
co
ho
rt
st
ud
y;
no
t
a
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y
Sm
ok
in
g
as
no
rm
al
pr
io
r
to
st
ar
tin
g
st
ud
y
A
bs
tin
en
tf
or
11
ho
ur
s
pr
io
r
to
pa
tc
h
pl
ac
em
en
t.
Tr
an
sd
er
m
al
pa
tc
h
21
m
g
w
or
n
fo
r
8
ho
ur
s
Sa
liv
a
ni
co
tin
e
an
d
co
tin
in
e
M
in
im
um
1
ho
ur
af
te
r
la
st
ci
ga
re
tt
e
8
ho
ur
s
af
te
r
of
st
ar
te
d
pa
tc
h
M
ea
n,
ra
ng
e
(μ
g/
l)c
Co
tin
in
e
va
lu
es
(n
=
6)
Sm
ok
in
g
10
0
(4
0–
15
5)
Pa
tc
h
55
(2
0–
10
0)
N
ic
ot
in
e
va
lu
es
(n
=
6)
sm
ok
in
g
19
(7
–
48
)
Pa
tc
h
19
(6
–
41
)
(C
on
ti
nu
es
)
7
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Ta
bl
e
1.
(C
on
tin
ue
d)
St
ud
y
Pa
rt
ic
ip
an
ts
po
te
nt
ia
lly
pr
ov
id
in
g
lo
ng
itu
di
na
l
da
ta
(n
)
Ch
ar
ac
te
ri
st
ic
s
of
pa
rt
ic
ip
an
ts
Se
tt
in
g,
de
si
gn
&
ex
po
su
re
s
B
od
y
ﬂ
ui
d
us
ed
an
d
as
sa
y
tim
in
gs
A
ss
ay
re
su
lts
O
gb
ur
n
et
al
.1
99
9
[3
6]
21
Va
lu
es
ar
e
m
ea
ns
±
SD
M
at
er
na
la
ge
26
.5
±
5.
7
G
es
ta
tio
n
at
en
ro
lm
en
t
27
.4
±
2.
7
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
20
.5
±
8.
7
U
ni
te
d
St
at
es
La
bo
ra
to
ry
-b
as
ed
co
ho
rt
st
ud
y;
no
t
a
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y
Sm
ok
in
g
as
us
ua
lp
ri
or
to
da
y
of
ad
m
is
si
on
A
bs
tin
en
ce
st
ar
te
d
on
ad
m
is
si
on
an
d
co
nt
in
ue
d
fo
r
in
-p
at
ie
nt
pe
ri
od
Tr
an
sd
er
m
al
pa
tc
h
22
m
g/
24
ho
ur
s
w
or
n
ea
ch
da
y
of
in
-p
at
ie
nt
st
ay
Bl
oo
d
ni
co
tin
e
an
d
co
tin
in
e
A
t
2
p.
m
.a
fte
r
a
no
rm
al
m
or
ni
ng
’s
sm
ok
in
g
an
d
at
le
as
t
10
m
in
ut
es
af
te
r
la
st
ci
ga
re
tt
e
O
n
al
lo
fd
ay
s
1–
4,
8
ho
ur
s
af
te
r
pa
tc
h
pl
ac
em
en
t
on
ea
ch
da
y
M
ea
n
±
SD
(n
g/
m
l)
Co
tin
in
e
va
lu
es
Sm
ok
in
g
11
6
±
54
(n
=
21
)
D
ay
1
pa
tc
h
14
2
±
47
(n
=
21
)
D
ay
2
pa
tc
h
12
8
±
38
(n
=
20
)
D
ay
3
pa
tc
h
12
3
±
42
(n
=
20
)
D
ay
4
pa
tc
h
11
7
±
38
(n
=
20
)
N
ic
ot
in
e
va
lu
es
Sm
ok
in
g
14
.4
±
9.
7
(n
=
20
)
D
ay
1
pa
tc
h
12
.7
±
4.
2
(n
=
21
)
D
ay
2
pa
tc
h
12
.8
±
4.
5
(n
=
20
)
D
ay
3
pa
tc
h
13
.7
±
6.
0
(n
=
20
)
D
ay
4
pa
tc
h1
1.
8
±
3.
9
(n
=
20
)
H
eg
aa
rd
,K
jæ
rg
aa
rd
,
M
øl
le
r,
W
ac
hm
an
n
&
O
tt
es
en
20
04
[2
9]
75
Va
lu
es
ar
e
m
ea
ns
±
SD
G
es
ta
tio
n
at
en
ro
lm
en
t
21
.5
±
8.
4b
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
12
.5
±
5.
2b
Va
lu
es
ar
e
ns
D
en
m
ar
k
Lo
ng
itu
di
na
lc
oh
or
t
st
ud
y;
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y
Sm
ok
in
g
as
no
rm
al
pr
io
r
to
st
ud
y
Fa
ge
rs
tr
öm
sc
or
e
us
ed
to
al
lo
ca
te
N
R
T;
hi
gh
er
sc
or
e,
hi
gh
er
do
se
us
ed
an
d
w
om
en
fo
llo
w
ed
up
in
3
pa
ra
lle
lg
ro
up
s
W
om
en
w
ith
Fa
ge
rs
tr
öm
sc
or
e
of
2–
4
us
ed
up
to
12
pi
ec
es
of
2
m
g
gu
m
da
ily
Fo
r
sc
or
es
of
4–
7,
15
m
g/
16
-h
ou
r
ni
co
tin
e
pa
tc
he
s
w
er
e
us
ed
Fo
r
sc
or
es
of
7–
10
,1
5
m
g/
16
-h
ou
r
ni
co
tin
e
pa
tc
he
s
pl
us
up
to
8
da
ily
pi
ec
es
of
2
m
g
gu
m
w
er
e
us
ed
Sa
liv
a
co
tin
in
e
Ba
se
lin
e
m
ea
su
re
m
en
tt
ak
en
be
fo
re
st
ar
tin
g
N
R
T,
w
hi
le
st
ill
sm
ok
in
g
bu
tn
o
tim
e
fr
om
la
st
ci
ga
re
tt
e
gi
ve
n
1–
2
w
ee
ks
af
te
r
sm
ok
in
g
ce
ss
at
io
n
w
hi
le
us
in
g
N
RT
an
d
ab
st
in
en
t;
no
tim
e
fr
om
la
st
gu
m
or
fr
om
pa
tc
h
pl
ac
em
en
t
gi
ve
n
M
ea
n
±
SD
(n
g/
m
l)
2
m
g
gu
m
(n
=
6)
Sm
ok
in
g
13
2
±
95
N
R
T
35
±
28
M
ea
n
di
ffe
re
nc
e,
95
%
CI
=
–9
7
(
6–
20
0)
Sm
ok
in
g
17
3
±
41
N
R
T
70
±
33
M
ea
n
di
ffe
re
nc
e,
95
%
CI
=
–1
03
(6
0–
14
6)
Pa
tc
h
15
m
g/
16
ho
ur
s,
2
m
g
gu
m
(n
=
5)
Sm
ok
in
g
24
6
±
91
N
R
T
10
5
±
51
M
ea
n
di
ffe
re
nc
e,
95
%
CI
=
–1
41
(4
7–
23
6)
Fa
ge
rs
tr
öm
va
lu
e
n
2–
4
6
4–
7
7
7–
10
5
(C
on
ti
nu
es
)
8 C. Hickson et al.
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Ta
bl
e
1.
(C
on
tin
ue
d)
St
ud
y
Pa
rt
ic
ip
an
ts
po
te
nt
ia
lly
pr
ov
id
in
g
lo
ng
itu
di
na
l
da
ta
(n
)
Ch
ar
ac
te
ri
st
ic
s
of
pa
rt
ic
ip
an
ts
Se
tt
in
g,
de
si
gn
&
ex
po
su
re
s
B
od
y
ﬂ
ui
d
us
ed
an
d
as
sa
y
tim
in
gs
A
ss
ay
re
su
lts
O
nc
ke
n,
Ca
m
pb
el
l,
Ch
an
,H
at
su
ka
m
i&
K
ra
nz
le
r
20
09
[3
0]
14
Va
lu
es
ar
e
m
ea
ns
±
SD
M
at
er
na
la
ge
Pa
tc
h
29
.8
6
±
6.
52
Sp
ra
y
30
.2
9
±
5.
09
G
es
ta
tio
n
at
en
ro
lm
en
t
Pa
tc
h
32
.0
6
±
2.
64
Sp
ra
y
31
.7
0
±
3.
2
D
ai
ly
co
ns
um
pt
io
n
of
ci
ga
re
tt
es
Pa
tc
h
19
.6
4
±
3.
66
Sp
ra
y
16
.7
1
±
5.
90
Fa
ge
rs
tr
öm
va
lu
e
Pa
tc
h
6.
71
±
1.
60
Sp
ra
y
6.
29
±
1.
11
Et
hn
ic
ity
da
ta
Ca
uc
as
ia
n
pa
tc
h
85
.7
%
;s
pr
ay
71
.4
%
U
ni
te
d
St
at
es
Lo
ng
itu
di
na
lc
oh
or
t
st
ud
y;
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y
W
om
en
sm
ok
ed
7
ci
ga
re
tt
es
ov
er
7
ho
ur
s
(1
pe
r
ho
ur
)
in
a
m
on
ito
ri
ng
se
ss
io
n
Th
en
th
ey
w
er
e
al
lo
ca
te
d
to
on
e
of
tw
o
ty
pe
s
of
N
RT
fo
r
4
da
ys
,o
r
th
e
pl
ac
eb
o
eq
ui
va
le
nt
.T
he
y
w
er
e
no
t
m
on
ito
re
d
du
ri
ng
th
e
4
da
ys
an
d
th
en
re
tu
rn
ed
fo
r
a
2n
d
m
on
ito
ri
ng
se
ss
io
n
N
R
T
us
ed
:
Tr
an
sd
er
m
al
pa
tc
h
15
m
g/
16
ho
ur
s
(1
pa
tc
h
pe
r
da
y)
.D
ur
in
g
m
on
ito
ri
ng
se
ss
io
n
pa
tc
h
w
as
pl
ac
ed
at
10
a.
m
.
N
as
al
sp
ra
y
(1
m
g/
do
se
)
do
se
=
1s
pr
ay
to
ea
ch
no
st
ri
l;
in
st
ru
ct
ed
to
us
e
up
to
24
da
ily
do
se
s.
D
ur
in
g
m
on
ito
ri
ng
se
ss
io
n
na
sa
ls
pr
ay
w
as
us
ed
tw
ic
e
at
th
e
eq
ui
va
le
nt
tim
es
to
ci
ga
re
tt
e
1,
4
an
d
7,
an
d
on
ce
in
pl
ac
e
of
th
e
2n
d,
3r
d,
5t
h
an
d
6t
h
ci
ga
re
tt
e
Se
ru
m
ni
co
tin
e
&
co
tin
in
e
(c
ot
in
in
e
us
ed
in
an
al
ys
is
)
1s
t
la
bo
ra
to
ry
-b
as
ed
sm
ok
in
g
se
ss
io
n;
af
te
r
ov
er
ni
gh
t
(8
ho
ur
s)
ab
st
in
en
ce
.
A
ss
ay
s
ta
ke
n
be
fo
re
an
d
af
te
r
1s
t
an
d
7t
h
ci
ga
re
tt
e
an
d
af
te
r
4t
h
ci
ga
re
tt
e;
av
er
ag
e
of
th
es
e
sa
m
pl
es
re
po
rt
ed
2n
d
la
bo
ra
to
ry
se
ss
io
n:
on
th
e
5t
h
tr
ea
tm
en
t
da
y,
af
te
r
ov
er
ni
gh
t
N
RT
ab
st
in
en
ce
.I
n
bo
th
pa
tc
h
an
d
sp
ra
y
gr
ou
ps
sa
m
pl
es
w
er
e
ta
ke
n
at
eq
ui
va
le
nt
tim
es
to
th
e
sm
ok
in
g
se
ss
io
n;
av
er
ag
e
of
th
es
e
sa
m
pl
es
re
po
rt
ed
M
ea
n
±
SD
(n
g/
m
l)
Pa
tc
h
(n
=
7)
sm
ok
in
g
13
8
±
55
Pa
tc
h
75
M
ea
n
di
ffe
re
nc
e
±
SD
6
3
±
33
Sp
ra
y
(n
=
7)
Sm
ok
in
g
13
0
±
57
N
R
T
se
ss
io
n
sp
ra
y
39
M
ea
n
di
ffe
re
nc
e
±
SD
9
1
±
38
(C
on
ti
nu
es
)
9
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Ta
bl
e
1.
(C
on
tin
ue
d)
St
ud
y
Pa
rt
ic
ip
an
ts
po
te
nt
ia
lly
pr
ov
id
in
g
lo
ng
itu
di
na
l
da
ta
(n
)
Ch
ar
ac
te
ri
st
ic
s
of
pa
rt
ic
ip
an
ts
Se
tt
in
g,
de
si
gn
&
ex
po
su
re
s
B
od
y
ﬂ
ui
d
us
ed
an
d
as
sa
y
tim
in
gs
A
ss
ay
re
su
lts
R
an
do
m
iz
ed
co
nt
ro
lle
d
tr
ia
ld
at
a
W
is
bo
rg
,H
en
ri
ks
en
,
Je
sp
er
se
n
&
Se
ch
er
20
00
[3
7]
12
4
ra
nd
om
iz
ed
to
ni
co
tin
e
Va
lu
es
ar
e
m
ea
ns
±
SD
M
at
er
na
la
ge
28
.2
±
4.
9b
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
13
.4
±
4.
0b
D
en
m
ar
k
R
an
do
m
iz
ed
co
nt
ro
lle
d
tr
ia
ls
tu
dy
;s
m
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y;
re
cr
ui
te
d
fr
om
A
ar
hu
s
H
os
pi
ta
l
W
om
en
ra
nd
om
iz
ed
to
N
RT
w
er
e
is
su
ed
w
ith
8
w
ee
k’
s
15
m
g/
16
ho
ur
s
ni
co
tin
e
pa
tc
he
s,
fo
llo
w
ed
by
a
fu
rt
he
r
3
w
ee
ks
of
10
m
g/
16
ho
ur
s
ni
co
tin
e
pa
tc
he
s
Sa
liv
a
co
tin
in
e
W
hi
le
st
ill
sm
ok
in
g
us
ua
la
m
ou
nt
:n
o
tim
e
fr
om
la
st
ci
ga
re
tt
e
re
po
rt
ed
A
t
8
&
11
w
ee
ks
fr
om
st
ar
tin
g
ni
co
tin
e
pa
tc
h
Fu
rt
he
r
as
sa
ys
at
4
w
ee
ks
be
fo
re
ex
pe
ct
ed
de
liv
er
y,
bu
t
un
cl
ea
r
w
he
th
er
N
RT
w
as
st
ill
su
pp
lie
d
M
ea
n
±
SD
(n
g/
m
l)
Sm
ok
in
g
(b
as
el
in
e)
(n
=
12
4)
23
1
±
12
5
8
w
ee
ks
d
pa
tc
h
(n
=
90
)
15
3
11
w
ee
ks
d
pa
tc
h
(n
=
83
)
12
1
4
w
ee
ks
d
pr
e-
de
liv
er
y
pa
tc
h
(n
=
75
)
12
0
O
nc
ke
n
et
al
.2
00
8
[3
8]
10
0
ra
nd
om
iz
ed
to
ni
co
tin
e
Va
lu
es
ar
e
m
ea
ns
±
SD
M
at
er
na
la
ge
25
.5
±
6.
8b
G
es
ta
tio
n
at
en
ro
lm
en
t
17
.1
±
5.
6b
D
ai
ly
co
ns
um
pt
io
n
of
ci
ga
re
tt
es
be
fo
re
pr
eg
na
nc
y
17
.5
±
9.
6b
la
st
7
da
ys
be
fo
re
en
ro
lm
en
t
10
.2
±
6.
6
Fa
ge
rs
tr
öm
va
lu
e
3.
83
±
1.
91
b
Va
lu
es
ar
e
ns
Et
hn
ic
ity
da
ta
b
U
ni
te
d
St
at
es
R
an
do
m
iz
ed
co
nt
ro
lle
d
tr
ia
l;
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y;
re
cr
ui
te
d
fr
om
H
ar
tfo
rd
,N
ew
Br
ita
in
,S
pr
in
gﬁ
el
d
m
ed
ic
al
si
te
s
W
om
en
ra
nd
om
iz
ed
to
N
RT
ar
m
w
er
e
en
co
ur
ag
ed
to
st
op
sm
ok
in
g
or
to
re
du
ce
th
e
nu
m
be
r
of
ci
ga
re
tt
es
sm
ok
ed
If
qu
itt
in
g
th
ey
w
er
e
in
st
ru
ct
ed
to
ch
ew
on
e
pi
ec
e
of
gu
m
fo
r
ev
er
y
ci
ga
re
tt
e
th
ey
us
ua
lly
sm
ok
ed
pe
r
da
y
an
d
to
be
gi
n
on
th
ei
r
qu
it
da
te
.I
fn
ot
ab
st
in
en
tt
he
y
w
er
e
to
ch
ew
on
e
pi
ec
e
of
gu
m
fo
r
ea
ch
ci
ga
re
tt
e
el
im
in
at
ed
;n
ot
ex
ce
ed
in
g
20
pi
ec
es
/d
ay
Th
ey
w
er
e
gi
ve
n
gu
m
fo
r
6
w
ee
ks
to
us
e
as
ab
ov
e
an
d
fo
ra
fu
rt
he
r6
w
ee
ks
to
ta
pe
r
th
e
am
ou
nt
us
ed
an
d
st
op
U
ri
ne
co
tin
in
e
W
hi
le
st
ill
sm
ok
in
g
us
ua
la
m
ou
nt
:n
o
tim
e
fr
om
la
st
ci
ga
re
tt
e
re
po
rt
ed
6
w
ee
ks
af
te
r
st
ar
tin
g
gu
m
&
32
–
34
w
ee
ks
ge
st
at
io
n
Fu
rt
he
r
m
ea
su
re
m
en
ts
ta
ke
n
at
3–
7
da
ys
,2
w
ee
ks
&
3
w
ee
ks
af
te
r
qu
it
da
te
,a
nd
6–
12
w
ee
ks
po
st
pa
rt
um
bu
t
va
lu
es
no
t
re
po
rt
ed
M
ea
n
±
SD
(n
g/
m
l)
Sm
ok
in
g
(b
as
el
in
e)
(n
=
93
)6
72
±
43
8
6
w
ee
ks
d
of
2
m
g
gu
m
(n
=
51
)
54
2
±
45
4
32
–
34
w
ee
ks
d
ge
st
at
io
n
af
te
r
N
R
T
tr
ea
tm
en
t
ﬁ
ni
sh
ed
(n
=
54
)
49
2.
45
±
44
3
H
is
pa
ni
c
53
N
on
-H
is
pa
ni
c
w
hi
te
38
N
on
-H
is
pa
ni
c
bl
ac
k
8
O
th
er
1
(C
on
ti
nu
es
)
10 C. Hickson et al.
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Ta
bl
e
1.
(C
on
tin
ue
d)
St
ud
y
Pa
rt
ic
ip
an
ts
po
te
nt
ia
lly
pr
ov
id
in
g
lo
ng
itu
di
na
l
da
ta
(n
)
Ch
ar
ac
te
ri
st
ic
s
of
pa
rt
ic
ip
an
ts
Se
tt
in
g,
de
si
gn
&
ex
po
su
re
s
B
od
y
ﬂ
ui
d
us
ed
an
d
as
sa
y
tim
in
gs
A
ss
ay
re
su
lts
El
-M
oh
an
de
s
et
al
.
20
13
[2
2]
26
ra
nd
om
iz
ed
to
ni
co
tin
e
Va
lu
es
ar
e
m
ea
ns
±
SD
M
at
er
na
la
ge
27
.5
±
5b
G
es
ta
tio
n
at
en
ro
lm
en
t1
9.
6
±
5.
1b
Et
hn
ic
ity
da
ta
b
A
ll
se
lf-
re
po
rt
as
a
m
in
or
ity
et
hn
ic
ity
BM
I
28
.1
±
10
.7
b
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
7
±
7.
4b
Va
lu
es
ar
e
ns
A
m
ou
nt
of
ci
ga
re
tt
e
U
ni
te
d
St
at
es
R
an
do
m
iz
ed
cl
in
ic
al
tr
ia
l;
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y;
re
cr
ui
te
d
fr
om
pr
en
at
al
ca
re
si
te
s
in
th
e
D
C
m
et
ro
po
lit
an
ar
ea
W
om
en
ra
nd
om
iz
ed
to
N
R
T
us
ed
tr
an
sd
er
m
al
14
-m
g
pa
tc
h
fo
r
ap
pr
ox
.2
–
4
w
ee
ks
be
fo
re
ﬁ
rs
t
sa
m
pl
in
g,
fo
llo
w
ed
by
tr
an
sd
er
m
al
7
m
g
pa
tc
h
fo
r
ap
pr
ox
.
2
w
ee
ks
be
fo
re
th
e
se
co
nd
sa
m
pl
in
g
So
m
e
w
om
en
re
ce
iv
ed
21
m
g
pa
tc
h
fo
r
ﬁ
rs
t
2
w
ee
ks
of
N
RT
du
e
to
hi
gh
er
ba
se
lin
e
co
tin
in
e
le
ve
ls
bu
t
w
ou
ld
ha
ve
be
en
on
14
m
g
pa
tc
h
at
tim
e
of
ﬁ
rs
ts
am
pl
in
g.
Sa
m
pl
es
w
er
e
al
so
ta
ke
n
la
te
r
w
he
n
it
is
un
cl
ea
r
if
w
om
en
w
er
e
st
ill
gi
ve
n
N
R
T
Sa
liv
a
co
tin
in
e
W
hi
le
st
ill
sm
ok
in
g
us
ua
la
m
ou
nt
:n
o
tim
e
fr
om
la
st
ci
ga
re
tt
e
re
po
rt
ed
A
fte
r
us
in
g
a
14
m
g
pa
tc
h
fo
ra
pp
ro
x.
2-
4
w
ee
ks
(a
nd
ha
vi
ng
be
en
us
in
g
N
R
T
fo
r
av
er
ag
e
3.
7
w
ee
ks
)
A
fte
r
us
in
g
a
7
m
g
pa
tc
h
fo
r
ap
pr
ox
.
2
w
ee
ks
(a
nd
ha
vi
ng
be
en
us
in
g
N
R
T
fo
r
av
er
ag
e
7.
8
w
ee
ks
)
M
ea
n
±
SD
(n
g/
m
l)
Sm
ok
in
g
(b
as
el
in
e)
(n
=
26
)
17
1
±
14
3
14
m
g
pa
tc
hd
(n
=
26
)
14
2c
7
m
g
pa
tc
hd
(n
=
26
)
12
9c
Sm
ok
e
al
lo
fa
ci
g.
7
Sm
ok
e
m
os
t
of
a
ci
g.
3
Sm
ok
e
ha
lf
a
ci
g.
15
In
ha
la
tio
n
In
ha
le
de
ep
ly
8
In
ha
le
m
od
er
at
el
y
10
In
ha
le
sl
ig
ht
ly
8
Be
rl
in
,G
ra
ng
é,
Ja
co
b
&
Ta
ng
uy
20
14
[3
9]
20
3
ra
nd
om
iz
ed
to
ni
co
tin
e
Va
lu
es
ar
e
m
ed
ia
n
&
in
te
rq
ua
rt
ile
ra
ng
e
M
at
er
na
la
ge
29
.1
(2
5–
34
)b
G
es
ta
tio
n
at
ra
nd
om
iz
at
io
n
17
(1
5–
20
)b
BM
I
pr
e-
pr
eg
na
nc
y
23
(2
0–
27
)b
Fr
an
ce
R
an
do
m
iz
ed
co
nt
ro
lle
d
tr
ia
l;
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y;
re
cr
ui
te
d
fr
om
m
at
er
ni
ty
w
ar
ds
N
ic
ot
in
e
pa
tc
h
be
tw
ee
n
10
–3
0
m
g/
da
y
ad
ju
st
ed
to
pa
rt
ic
ip
an
tc
ot
in
in
e
le
ve
l
(m
ea
n
±
SD
=
18
±
6.
8
m
g/
da
y)
us
ed
fr
om
qu
it
da
te
un
til
de
liv
er
y
w
ith
br
ie
fs
m
ok
in
g
la
ps
es
pe
rm
itt
ed
Sa
liv
a
co
tin
in
e
W
hi
le
st
ill
sm
ok
in
g
us
ua
la
m
ou
nt
:n
o
tim
e
fr
om
la
st
ci
ga
re
tt
e
re
po
rt
ed
2
w
ee
ks
af
te
r
qu
it
da
te
w
hi
le
us
in
g
ni
co
tin
e
pa
tc
h
8
w
ee
ks
af
te
r
qu
it
da
te
w
hi
le
us
in
g
ni
co
tin
e
pa
tc
h
M
ea
n
±
SE
(μ
g/
l)
Sm
ok
in
g
(b
as
el
in
e)
11
9
±
1.
09
2
w
ee
ks
pa
tc
hd
10
8
±
1.
1
8
w
ee
ks
pa
tc
hd
80
±
1.
1
(C
on
ti
nu
es
)
11
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Ta
bl
e
1.
(C
on
tin
ue
d)
St
ud
y
Pa
rt
ic
ip
an
ts
po
te
nt
ia
lly
pr
ov
id
in
g
lo
ng
itu
di
na
l
da
ta
(n
)
Ch
ar
ac
te
ri
st
ic
s
of
pa
rt
ic
ip
an
ts
Se
tt
in
g,
de
si
gn
&
ex
po
su
re
s
B
od
y
ﬂ
ui
d
us
ed
an
d
as
sa
y
tim
in
gs
A
ss
ay
re
su
lts
D
ai
ly
ci
ga
re
tt
e
co
ns
um
pt
io
n
11
(8
–1
5)
b
Fa
ge
rs
tr
öm
va
lu
e
5
(3
–6
)b
Va
lu
es
ar
e
ns
Et
hn
ic
ity
da
ta
b
Eu
ro
pe
an
19
4
A
fr
ic
an
6
A
si
an
1
O
th
er
2
Ti
m
e
to
ﬁ
rs
t
ci
ga
re
tt
eb
>
60
m
in
ut
es
31
31
–6
0
m
in
ut
es
36
6–
30
m
in
ut
es
74
≤
5
m
in
ut
es
62
U
nc
le
ar
ho
w
m
an
y
w
om
en
sa
m
pl
ed
at
ea
ch
vi
si
t
Bo
w
ke
r,
Le
w
is
,
Co
le
m
an
,V
az
&
Co
op
er
20
14
[4
0]
33
Va
lu
es
ar
e
m
ed
ia
n
&
in
te
rq
ua
rt
ile
ra
ng
e
M
at
er
na
la
ge
26
.1
2
(2
2.
29
–3
2.
35
)
G
es
ta
tio
n
at
ba
se
lin
e
14
.4
(1
3.
3–
17
.8
)
Et
hn
ic
ity
da
ta
A
ll
w
hi
te
ex
ce
pt
on
e
A
si
an
/o
th
er
BM
I
25
.6
(2
2.
7–
29
.3
)
W
om
en
w
ith
pa
rt
ne
rs
w
ho
sm
ok
e
23
(7
0%
)
U
ni
te
d
K
in
gd
om
Se
co
nd
ar
y
an
al
ys
is
of
da
ta
fr
om
in
te
rv
en
tio
n
ar
m
of
ra
nd
om
iz
ed
co
nt
ro
lle
d
tr
ia
lo
fN
R
T;
sm
ok
in
g
ce
ss
at
io
n
in
te
rv
en
tio
n
st
ud
y;
re
cr
ui
te
d
fr
om
an
te
na
ta
lc
lin
ic
s
Tr
an
sd
er
m
al
pa
tc
h
15
m
g/
16
ho
ur
us
ed
fo
r
up
to
2
m
on
th
s
af
te
r
qu
it
da
te
w
hi
le
re
m
ai
ni
ng
ab
st
in
en
t;
in
st
ru
ct
ed
to
st
op
N
RT
if
sm
ok
in
g
re
-s
ta
rt
s
Sa
liv
a
co
tin
in
e
W
hi
le
st
ill
sm
ok
in
g
us
ua
la
m
ou
nt
:n
o
tim
e
fr
om
la
st
ci
ga
re
tt
e
re
po
rt
ed
4
w
ee
ks
fr
om
qu
it
da
te
w
hi
le
us
in
g
15
m
g/
16
-h
ou
r
ni
co
tin
e
pa
tc
h
an
d
ab
st
in
en
t
R
ep
or
te
d
di
ffe
re
nc
e
in
co
tin
in
e
fr
om
sm
ok
in
g
to
N
RT
us
e
w
he
n
st
ar
tin
g
Co
tin
in
e
le
ve
l>
15
0
ng
/m
la
nd
w
he
n
<
15
0
ng
/m
l
M
ed
ia
n
&
in
te
rq
ua
rt
ile
ra
ng
e
(n
g/
m
l)
Sm
ok
in
g
(n
=
33
)
98
.5
(7
1.
3–
17
7.
8)
N
RT
(a
bs
tin
en
t)
(n
=
33
)
62
.8
(3
3.
3–
82
.7
)
M
ed
ia
n
co
tin
in
e
di
ffe
re
nc
e
w
ith
ba
se
lin
e
co
tin
in
e:
>
15
0
ng
/m
l
1
34
.8
<
15
0
ng
/m
l–
27
.9
(C
on
ti
nu
es
)
12 C. Hickson et al.
© 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
The fourth [35] had inconsistent ﬁndings; peak exposure
(mean maximal plasma nicotine) was higher but total ex-
posure (area under a nicotine concentration versus time
graph) was lower after smoking.
Row 10 describes a longitudinal cohort study in which
women were followed-up daily for 4 days when abstinent
after starting NRT [36]; cotinine levels (Table 3) were
higher and nicotine levels (not shown) were lower at all
follow-up points, with the day 1 cotinine difference
reaching statistical signiﬁcance. For three follow-up com-
parisons, a participant (from 21) was lost to follow-up
(Table 1).
Rows 11 and 12 describe women in NRT arms of RCTs
[22,37]; in both studies, exposures (group mean cotinine
levels) were higher in smokers at baseline, but it was not
possible to identify separately those using NRT and
abstinent.
DISCUSSION
Ameta-analysis comparing cotinine exposures when preg-
nant women smoke with those when they use NRT found
that levels were, on average, 75.3 ng/ml lower when absti-
nent and using NRT than when the same women smoked.
Similarly, lower exposures after NRT occurred in six of the
remaining eight studies.
Only 12 empirical studies were included; ﬁve had not
been designed as longitudinal cohorts and most did not
publish sufﬁcient details to be included in a meta-analysis.
Nevertheless, longitudinal, within-participant data were
available from 10 studies and so only two were of limited
use for answering review questions [22,37]. Participants
were recruited to either hospital in-patient/laboratory
studies with intensive protocols or into clinical trials, but
the consistency of outcomes from studies in very different
settings suggests the principal ﬁnding that using NRT ex-
poses pregnant women who are fully abstinent from
smoking to less nicotine than smoking is valid. Although
the amount of useable data from studies was small, by fo-
cusing on ‘within-individual’ differences in cotinine levels,
study women effectively acted as their own controls and
external impacts on cotinine levels, apart from of NRT
doses used, were eliminated. Only factors which changed
within individual women between baseline and follow-up
could be expected to affect the pooled estimate formean dif-
ference in cotinine levels. One such factor is the rate of nic-
otine metabolism, which is signiﬁcantly accelerated by the
second trimester [15]. Adjusting ﬁndings for increasing
rates of nicotine metabolism as pregnancy progressed
could have helped us to understand how much lower co-
tinine levels on NRT might be attributable to faster metab-
olism; however, this was beyond the scope of the review.
Nevertheless, there are two reasons to suspect that in-
creased nicotine metabolism had little overall impact onTa
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ﬁndings. First, the mean differences from studies which
measured these only hours after stopping smoking
[23,34,35] were comparable to those in whom cotinine
(nicotine) levels on NRT were measured weeks afterwards
or even later in pregnancy [22,37–40]. Secondly, ﬁndings
from those studies which recruited more women whowere
under 18 weeks gestation [38–40] appeared similar to re-
maining studies which recruited later in pregnancy.
We believe this study is original, and the systematic
approach used combined with the rigorous contact made
with authors should have sourced all available data
within identiﬁed studies. Despite substantial variation in
the types of NRT issued and in how participants were
instructed to use this, and also in the timings of sample
measurement across studies, the low level of heterogene-
ity in the pooled mean difference estimate indicates that
Table 2 Quality assessment of cohort studies.
Study Representativeness
Ascertainment of
exposures
Method for conﬁrming
abstinence
Appropriateness
sample timing
Completeness of
follow-up
Stars (out
of 7)
Gennser
1975 [33]
– * * * ** 5*
Oncken 1996
[34]
** * * – * 5*
Oncken 1997
[35]
** – * – ** 5*
Wright 1997
[23]
– – * – ** 3*
Ogburn 1999
[36]
* – * – * 3*
Hegaard
2004 [29]
* – * – – 2*
Oncken 2009
[30]
** * * * ** 7*
Figure 2 Forest plot showingmeta-analysis of mean difference in saliva cotinine levels when smoking and when abstinent but using nicotine replace-
ment therapy (NRT). Hegaard1, Hegaard2 and Heggard3 2004 represent cohorts of women given different forms of NRT and reported in Hegaard
2004 [29]; ditto for Oncken1 and Oncken2 2009 and Oncken 2009 [30] [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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Table 3 Source and derivation of mean differences used in review.
Studies in meta-analysis
Row Study
Participants abstinent on
NRT, providing
longitudinal data and loss
to follow up (n)
Body ﬂuid &
assay times
(i.e. after
starting NRT)
Type and dose of
NRT
Outcomesb
Derivation of outcome data
Mean difference
(SEMD)d (ng/ml)
Percentage
substitution
(%)
1 Hegaard
2004 [29]
18 analysed Saliva
cotinine,
2 weeks
2 mg gum
(n = 6)
97 (51.5) 26.5 Mean differences taken directly from
paper SEMs calculated from CI
presented in paperOf 75 enrolled 40 were
excluded:
15 mg/16-hour
patch (n = 7)
103 (21.5) 40.5
16 dropped out
13 stopped NRT 15 mg/16-hour
patch and 2 mg
gum (n = 5)
141 (47.5) 42.7
11 smoked the day
before second sample
17 were not analysed:
15 samples not collected
or not treated properly
or went missing
2 used a 10-mg patch
2 Oncken
2009 [30]
14 Serum
cotinine,
4 days
15 mg/16-hour
patch (n = 7)
63 (12.47) 54.3 Mean differences taken directly from
paper
Spray 24 dose/
day = 24 mg/
24 hours
(n = 7)
91 (14.36) 30.0 SEM calculated from SD of difference
3 Bowker
2014 [40]
33 Saliva
cotinine,
4 weeks
15 mg/16-hour
patch
51.2 (10.77) 60.0 Mean difference and SEM calculated
using original study data
4 Berlin
2014 [39]
18 Saliva
cotinine, 2
weeksc
Patch, variable
strength
70.22 (20.07) 49.3 Mean difference and SEM of abstinent
women only calculated by study
author using original study data
Narratively reported studies
Studies with additional data from authors
Row Study
Participants abstinent
on NRT, providing
longitudinal data and
loss to follow-up (n)
Body ﬂuid &
assay times
(i.e. after
starting NRT)
Type and
dose of
NRT
Outcomesb
Derivation of outcome
data/reason for
non-inclusion in
meta-analysis
Mean difference
(SEMD)d
(ng/ml)
Percentage
substitution (%)
5 Oncken
2008
[38]
4 Urine cotinine,
6 weeks
2 mg gum
(n = 4)
130.00
(245.738)
65.2 Mean difference and SD
of abstinent women using
gum at 6 weeks calculated
by author from original
data
Not included in meta-
analysis as urine rather
than saliva cotinine value
Studies where only published data used
Row Study
Participants abstinent
on NRT, providing
longitudinal data and
loss to follow-up (n)
Type & dose of NRT
body ﬂuid & assay times
(i.e. after starting NRT)
Outcomesb (ng/ml
unless stated otherwise)
Reasons for non-inclusion
in meta-analysis
6 Gennser
1975 [33]
Unclear: 12 participants
smoked at baseline, 6
were later using NRT but
it is not clear which of
the original 12 these
were
Gum, 2 & 4 mg Blood
nicotine, 30 minutes
Mean ± SEM Only group means and their standard
errors presented in paper; standard error
of mean difference could not be calculated
Cig. 19.6 ± 1.4 (n = 12)
2 mg gum 10.0 ± 0.7 (n = 6)
Difference in means calculated by review
team as (group mean value for smoking) –
(group mean value for gum use)
Difference in means = 9.6
Cig. 19.6 ± 1.4 (n = 12)
4 mg gum14.7 ± 1.3 (n = 6)
Difference in means = 4.9
7 Oncken
1996 [34]
15 Gum, 2 mg blood
cotinine, 5 days
Mean ± SD Only group means and their standard
errors presented in paper; standard error
of mean difference could not be calculated
Of 19 enrolled 4
dropped out: 2 due
to non-abstinence 2
suffered severe nausea
Smoking 153 ± 18
5 days gum 33 ± 8
Difference in means = 120 Difference in means calculated by review
team as (group mean value for smoking) –
(group mean value for gum use)
(Continues)
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the data synthesis undertaken was valid and the estimate
is robust.
It was not possible to combine studies’ ﬁndings to inves-
tigate the impacts of different NRT doses or regimens on co-
tinine levels. However, consideration of individual studies’
ﬁndings does not suggest that different NRT doses or giving
different instructions about using NRT has substantial im-
pact. For example, the mean differences in cotinine levels
obtained when smoking and later from women who were
abstinent and used NRT, and so were adherent, were
Table 3. (Continued)
Studies where only published data used
Row Study
Participants abstinent
on NRT, providing
longitudinal data and
loss to follow-up (n)
Type & dose of NRT
body ﬂuid & assay times
(i.e. after starting NRT)
Outcomesb (ng/ml
unless stated otherwise)
Reasons for non-inclusion
in meta-analysis
8 Oncken
1997 [35]
15 Patch, 21 mg blood
nicotine/hour
Mean ± SD (overlap:
smoking group lower
cotinine than patch
group)
Only group means and their standard
errors presented in paper; standard error
of mean difference could not be calculatedOf 17 enrolled 2 were
excluded: 1 single
uterine artery 1 quit
smoking after session 1
Difference in maximal plasma level
calculated as (smoking maximal level) –
(patch maximal level)
Mean maximal plasma level
Mean difference of areas under the plasma
nicotine concentration time curve taken
directly from paper
Smoking 19.7 ± 8.09
Patch 16.0 ± 3.5
Difference in mean maximal
plasma level 3.7
Time to reach max.
Smoking 5 hours ± 2.4
Patch 3.2 hours ± 1.7
Area under the plasma nicotine
concentration time curve
Smoking 89 ng-hour/ml
Patch 93 ng -hour/ml
Mean difference ± SEM
of area under the plasma
nicotine concentration
time curve
 4.8 ± 10.3 ng-hour/ml
9 Wright
1997 [23]
6 Patch, 21 mg saliva
cotinine, 8 hours
aMean & range (μg/l) Only group means and their standard
errors presented in paper; standard error
of mean difference could not be calculated
Smoking 100 (40–155)
Patch 55 (20–100)
Difference in means = 45 Difference in means
calculated by review
team as (group mean
value for smoking) –
(group mean value
for gum use)
10 Ogburn
1999 [36]
21 no reason given
for missing data
Patch, 21 mg blood
cotinine, day 1–4
Mean ± SD Only group means and their standard
errors presented in paper; standard error
of mean difference could not be calculated
Cotinine values
Smoking 116 ± 54 (n = 21)
Day 1 patch 142 ± 47 (n = 21)
Day 2 patch 128 ± 38 (n = 20)
Day 3 patch 123 ± 42 (n = 20)
Day 4 patch 117 ± 38 (n = 20) Difference in means calculated by review
team as, (group mean value for smoking)
– (groupmeanvalue for gumuse); missing
data ignored
Difference in means
Days 1–26
Days 2–12
Days 3–7
Days 4–1
11 Wisborg
2000 [37]
Unclear, as not all
participants were
abstinent when
assays taken
Patch 15 mg,
10 mg Saliva
cotinine, 8 &
11 weeks
Mean ± SD Not all participants abstinent when assays
occurred; only cross-sectional data
available in published report
Smoking (n = 124)
231 ± 125 8 weeks
(15 mg) patch (n = 90)
153 Difference in means at 8 weeks,
78
11 weeks (10 mg) patch (n = 83)
121. Difference in means at
11 weeks, 110
12 El-Mohandes
2013 [22]
Unclear, as not all
participants were
abstinent when
assays taken
Patch, 14 mg, 7 mg
Saliva cotinine,
approx.2–4 &
approx. 4–6 weeks
Mean ± SD (ng/ml) (n = 26) Not all participants abstinent when assays
occurred; only cross-sectional data
available in published report
Baseline 171 ± 143 14-mg patcha
142. Difference in means 39
Difference in means calculated by review
team as, (mean value for patch use) –
(mean value for smoking)
Baseline 171 ± 143 7-mg patcha
129 Difference in means 42
aData valued obtained using WebPlotDigitizer [24]. bA negative mean difference/difference between means indicates higher cotinine/nicotine levels when
smoking. cData from one of two follow-up times selected to avoid inclusion of non-independent observations in meta-analysis. dStandard error of the mean
(SEM) difference. SD = standard deviation; CI = conﬁdence interval; NRT = nicotine replacement therapy; BMI = body mass index.
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similar in two major RCTs investigating NRT in which
participants were told to use this treatment in different
ways [39,41]. In one trial [41], a single nicotine patch dose
was provided for only an 8-week treatment course and
participants were instructed to remove patches during
smoking lapses. In the other trial, however, nicotine patch
doses were personalized, and there was potential for higher
doses to be delivered to women who were told that they
could continue using NRT during brief smoking lapses
and even for the whole of pregnancy, if desired [39]. The
meta-analysis showed that cotinine levels when abstinent
and onNRTwere reduced, on average, by 70.3 ng/ml com-
pared to smoking, and throughout the four meta-analysis
studies cotinine levels when smoking varied between 99
and 246 ng/ml, suggesting that reductions in nicotine ex-
posure while using NRT are clinically meaningful. Review
studies, SNIPP excepted [39], used standard rather than
higher doses of nicotine patches and these delivered no
more than 15 mg cotinine in 16 hours or the 24-hour
equivalent. An important, unequivocal message is, there-
fore, that when pregnant smokers become abstinent
and adhere with to ‘standard’ doses of NRT they are, on
average, exposed to less nicotine than from smoking. One
arm of one study delivered both 15 mg/16-hour nicotine
patches and 2 mg gum to ﬁve women [29] who had high
baseline cotinine levels when smoking [mean (SD)] 246
(91) ng/ml, and themean difference (95%CI) between this
and cotinine levels on NRT was large [mean difference
(95% CI)] –141 (47–236). This estimate lacks precision,
however, and provides no evidence that higher-dose NRT
might expose women to more nicotine; nevertheless, more
studies are needed.
A key reason for this study was to determine whether
pregnant smokers who have concerns about the safety of
nicotine in pregnancy and which might deter them from
using NRT regularly enough and in sufﬁciently high doses
to help them stop smoking could be reassured about its use
[18,40]. The review demonstrates clearly that NRTexposes
pregnant women to much smaller nicotine doses than
smoking and, clearly, pregnant women considering NRT
use in pregnancy can be strongly reassured on this point.
It was not an aim of this paper to determine whether or
not nicotine is harmful to the developing baby; however,
the accruing literature suggests that this is not the case. Al-
though rodent studies have suggested that fetal nicotine
exposure may cause infant behavioural problems [42],
the only RCT of NRT for smoking cessation in pregnancy
found that NRT group infants had better developmental
outcomes [43]. Additionally, large studies of NRT used in
routine health care have found no consistent relationship
between NRT use in pregnancy and stillbirth [44,45], con-
genital abnormalities [46,47], preterm birth [48], low birth
weight [49] or strabismus [50]. It seems most probable
that most, if not all, the fetal harms caused by smoking in
pregnancyare due to other tobacco smoke toxins. Pregnant
women should avoid unnecessary toxin exposure and,
compared to smoking, NRT both eliminates exposure to
numerous tobacco smoke toxins and reduces nicotine expo-
sure. However, NRT also has great potential for improving
fetal health and averting adverse pregnancy outcomes by
helping some pregnant women to stop smoking. Review
ﬁndings could, therefore, help to reassure pregnant women
about the probable safetyof usingNRT tomaintain smoking
abstinence and also about the use of higher-dose NRT. Al-
though using ‘dual NRT’, an NRT patch and a short-acting
NRT together would generate higher nicotine exposures,
‘standard NRT dose’-generated nicotine exposure in
abstinent pregnantwomen is somuch lower than that from
smoking that dual NRT could well also deliver lower
nicotine doses than cigarettes. However, ‘dual NRT’ would
be more likely to alleviate withdrawal symptoms and so
womenwould probably use this for longer; thismayexplain
why an observational analysis of UK Stop Smoking Ser-
vices’ routine data found dual NRT but not standard-dose
NRT associated with smoking cessation in pregnancy [51].
CONCLUSIONS
Among pregnant women who quit smoking, standard-
dose NRT generates lower nicotine exposure than smoking.
This lower exposure, combined with the very strong likeli-
hood that nicotine is not responsible for the majority of
fetal harms caused by tobacco smoke, makes it very likely
that relative to smoking, NRT is safer for the fetus than
smoking. Additionally, when NRT promotes maternal
smoking cessation this is very likely to improve fetal health
by reducing adverse pregnancy outcomes.
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